New
HealthMore in Health→
Roivant's Dealmaking Playbook and the Curious Origins of a Lung Drug
Key Takeaways
- Roivant's lung disease drug succeeded in a mid-stage study, per STAT's Adam Biotech Scorecard.
- STAT's Adam Feuerstein frames the drug's origins as a particularly fascinating part of the story.
- Roivant is characterized as one of the savviest dealmakers in biotech and reportedly possesses a 'secret weapon.'
- The same STAT newsletter previews what to expect from UniQure's upcoming Huntington's gene therapy readout.
DE
DT Editorial Team··via statnews.com